Literature DB >> 1458685

In vitro preactivated human T cells engraft in SCID mice and migrate to murine lymphoid tissues.

N Armstrong1, F Cigel, W Borcherding, R Hong, V Malkovska.   

Abstract

Mice with severe combined immunodeficiency (SCID) accept grafts of human T and B lymphocytes derived from resting peripheral blood mononuclear cells (PBMC). We wished to determine whether activated human T cells engraft and migrate into lymphoid tissues in SCID mice. PBMC (50 x 10(6)) activated in vitro in a 4-day mixed lymphocyte culture (MLC) were injected into the peritoneum of 12 SCID mice. In 11 of 12 animals killed at 3 or 4 weeks after injection, human cells were detected in cells pooled from lymphoid organs by flow cytometry and by immunohistochemical staining of frozen tissue sections. The percentage of CD45+ cells in the 11 mice ranged from 2% to 45% and the absolute numbers of CD45+ cells recovered from lymphoid organs ranged from 4 x 10(6) to 90 x 10(6). Up to 93% of the human cells expressed the CD3 antigen together with either CD4 or CD8. Human T cells were localized in periarteriolar areas in murine spleens, whereas in the lymph nodes and gut mucosa, the T cells did not show the pattern for T-dependent areas found in human lymphoid tissue. Numerous human plasma cells were detected in the spleen and gut mucosal crypts of engrafted SCID mice. Human IgG was detected in the serum of all 11 engrafted SCID mice. The functional activity of human T cells recovered from murine splenic tissue was very low 3-4 weeks after engraftment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458685      PMCID: PMC1554564          DOI: 10.1111/j.1365-2249.1992.tb05870.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism.

Authors:  B A Malynn; T K Blackwell; G M Fulop; G A Rathbun; A J Furley; P Ferrier; L B Heinke; R A Phillips; G D Yancopoulos; F W Alt
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

2.  The scid mutation in mice causes a general defect in DNA repair.

Authors:  G M Fulop; R A Phillips
Journal:  Nature       Date:  1990-10-04       Impact factor: 49.962

3.  Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor.

Authors:  B M Mueller; C A Romerdahl; J M Trent; R A Reisfeld
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

4.  A model of human acute lymphoblastic leukemia in immune-deficient SCID mice.

Authors:  S Kamel-Reid; M Letarte; C Sirard; M Doedens; T Grunberger; G Fulop; M H Freedman; R A Phillips; J E Dick
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

5.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

6.  Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.

Authors:  K J Helzlsouer; G B Gordon; A J Alberg; T L Bush; G W Comstock
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

Review 7.  Immunodeficient mice xenografted with human lymphoid cells: new models for in vivo studies of human immunobiology and infectious diseases.

Authors:  D E Mosier
Journal:  J Clin Immunol       Date:  1990-07       Impact factor: 8.317

8.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

9.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

Authors:  I G Schmidt-Wolf; R S Negrin; H P Kiem; K G Blume; I L Weissman
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

10.  Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood.

Authors:  M Tary-Lehmann; A Saxon
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  6 in total

1.  Tetanus toxoid-specific T cell responses in severe combined immunodeficiency (SCID) mice reconstituted with human peripheral blood lymphocytes.

Authors:  R Somasundaram; L Jacob; D Herlyn
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

2.  Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo.

Authors:  W O Böcher; H Marcus; R Shakarchy; B Dekel; D Shouval; E Galun; Y Reisner
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

3.  Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity.

Authors:  V Malkovska; F Cigel; B E Storer
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

4.  The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice.

Authors:  W Walker; G Gallagher
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

5.  Infection of SCID mice with Mycobacterium leprae and control with antigen-activated "immune" human peripheral blood mononuclear cells.

Authors:  P J Converse; V L Haines; A Wondimu; L E Craig; W M Meyers
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

6.  Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras.

Authors:  M Tary-Lehmann; P V Lehmann; D Schols; M G Roncarolo; A Saxon
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.